INTRODUCTION
be histological assessment of the duodenum for mucosal healing. However, this method is invasive, costly, and carries risks of complications such as bleeding, perforation, and cardiopulmonary complications from sedation ( 14, 15 ) . Furthermore, there is little consensus for routine follow-up biopsy and the timing of re-biopsy among individual practice and national guidelines (16) (17) (18) (19) .
Th ere is certainly an unmet need for a reliable surrogate marker for histological remission in CD. A myriad of novel markers such as serum intestinal fatty acid-binding protein levels ( 20 ) , urinary and fecal gluten immunogenic peptide ( 21 ) , citrulline ( 22 ) , fecal fat excretion ( 23 ) , urinary lactulose-to-mannitol excretion ratios ( 24 ) , and the maximum concentration of simvastatin in the small intestine ( 25 ) have been studied, but none of them are currently used in widespread routine clinical practice.
At present, a combination of dietetic evaluation, symptom assessment and serological titers are used during follow-up, to determine the necessity for a repeat duodenal biopsy. However, these non-invasive surrogate markers have been shown to correlate poorly with persistent VA. Previous studies have shown a weak association between histological recovery and serology such as tissue transglutaminase (TTG) antibodies and endomysial (EMA) antibodies ( 10, (26) (27) (28) (29) . Dietary assessment by a specialist dietitian may currently be the optimal method of measuring adherence ( 30 ) , although the method of assessment is not standardized.
For all these reasons, a simple and reliable method of assessment to measure dietary adherence is needed. A dietary assessment questionnaire was devised by Biagi et al. ( 31 ) , which contains four simple questions based on the patients' strategy for gluten avoidance rather than assessing the amount of gluten ingested. Biagi et al. ( 31 ) reported that the adherence score identifi ed patients in histological remission, with a positive predictive value of 35.7% and negative predictive value (NPV) of 86.7%. Further studies are required to validate the utility of this questionnaire.
Several point-of-care tests (POCTs) detecting celiac antibodies have been developed over the past decade. Most of the POCTs detect TTG using lateral fl ow immunochromotography, such as Biocard, Celiac Quick Test, and Stick CD1 and 2, with the exception of Simtomax, which detects deamidated gliadin peptide (DGP) antibodies. Th ere is an abundance of studies investigating the performance of POCTs in the diagnosis of CD, with sensitivities of the aforementioned POCTs reported to be 58-100% (32) (33) (34) (35) (36) (37) (38) (39) (40) . A recent head to head trial of Simtomax, Biocard, and Celiac Quick Test demonstrated that Simtomax outperformed the other two, with sensitivities of 94.4%, 72.2%, and 77.8%, respectively ( 32 ) . On the other hand, there is a paucity of studies examining the role of POCTs in disease monitoring. Previous studies showed the sensitivities were found to be 78.9% for Simtomax ( 36 ) , and 77.8% (using whole blood) and 93.5% (using serum) for Celiac Quick Test in measuring dietary adherence in known CD ( 39 ) . However, these results should be interpreted with caution, as they did not use the presence of VA as the marker for non-adherence, but instead compared the POCT against TTG.
We aimed to evaluate the diagnostic performance of Simtomax, a commercially available IgA/IgG-DGP-based POCT, TTG, EMA, and the adherence questionnaire devised by Biagi et al. ( 31 ) in predicting persistent VA in patients with CD on a gluten-free diet.
METHODS

Study design and patients
Th e study took place at the Royal Hallamshire Hospital, Sheffi eld, UK, from March 2013 to January 2017. We prospectively recruited consecutive patients with biopsy-proven CD on a gluten-free diet, who were being assessed for histological remission. Inclusion criteria included those who were symptomatic, non-adherent to their gluten-free diet, or those with raised serological titers. Patients who were asymptomatic, adherent to their diet, and with negative serology were not routinely referred for a repeat duodenal biopsy in our center. Written consent for the study was obtained before their blood tests and gastroscopies. All patients were concurrently tested with IgA-TTG, IgA-EMA, total IgA levels, and the POCT Simtomax. A dietary adherence questionnaire was completed in the endoscopy unit. A gastroscopy with duodenal biopsies was then performed in all patients. Figure 1 demonstrates the fl ow of participants.
POCT Simtomax
Simtomax is a POCT for CD manufactured by Augurix Diagnostics, Rheinfelden, Switzerland. It detects both IgA-DGP and IgG-DGP, as well as the presence of IgA. Th e assay is based on lateral fl ow immunochromatography using colloidal gold antihuman antibodies as a signal detector. A sample of 25 μ l of capillary venous blood was obtained through a simple fi nger prick technique. Th e blood sample was then applied to the test device, followed by the application of fi ve drops of the provided buff er solution. Th e result was available aft er 10 min. Positive results were indicated by the presence of a solid red test line for IgA-DGP and/or IgG-DGP positivity. A second single red line indicated the presence of IgA. An in-built red control line ensured a correctly functioning test.
Celiac serology
TTG antibodies were assayed using enzyme-linked immunosorbent assay kits (Aesku Diagnostics, Wendelsheim, Germany). A TTG titer of >15 U ml −1 before 20 May 2014, a new cutoff level of >9 U ml −1 from 20 May 2017 to 11 December 2014, and then >7 U ml −1 from 12 December 2014 onwards, were regarded as positive as per the manufacturer's guidance. IgA-EMA was detected by immunofl uorescence on primate esophagus sections (Binding Site, Birmingham, UK). Total IgA was measured on a Behring BN2 nephelometer (Haywards Heath, West Sussex, UK). DGP assays were not available in our center and therefore not performed in our study.
Dietary adherence questionnaire
Th e validated dietary adherence questionnaire devised by Biagi et al. ( 31 ) consisted of four simple questions. It gives a 5-point score (0-4), with scores 3-4 indicating strict dietary adherence and scores 0-2 indicating non-adherence. Th is questionnaire was administered to the patients at the endoscopy unit before their gastroscopy. Th e adherence questionnaire is displayed in Figure 2 .
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Histological evaluation
In total, at least fi ve biopsies were taken from the duodenum with a single bite per pass technique, including at least one biopsy from the duodenal bulb and four quadrantic biopsies from the second part of the duodenum. Each biopsy was fi xed in formalin at the time of the gastroscopy. Specimens were then processed, orientated, and embedded in paraffi n wax by the pathology department. Standard 3 μ m-thick sections at three levels were stained with hematoxylin and eosin, and reported by gastrointestinal histopathologists without knowledge of the Simtomax or serology results. VA was graded according to the modifi ed Marsh criteria. Patients with March 0-2 histology without VA were considered to be in histological remission for the purpose of diagnostic accuracy calculations.
Ethical considerations
Th e study protocol was approved by the Yorkshire and the Humber Research Ethics committee and registered with the local research and development department of Sheffi eld Teaching Hospital NHS Foundation Trust under the registration number STH15416. Written consent was obtained from all patients.
Statistical analysis
Data were summarized by descriptive statistics, including counts and percentages for categorical data and medians and ranges for continuous parameters. Univariate analysis of patient characteristics was performed using χ 2 -test. Th e diagnostic accuracies of TTG, EMA, Simtomax, and the adherence score in detecting ongoing VA were presented with sensitivity, specifi city, positive and negative predictive value (NPV), measuring against duodenal histology as the reference standard. Clopper-Pearson method was used to calculate the confi dence intervals for the diagnostic test sensitivities. Sensitivities of the tests were compared using the McNemar test for correlated proportions. Receiver operating characteristic (ROC) curves were constructed with paired sensitivities and specifi cities of each surrogate marker, and the area under the curve was determined, using IBM SPSS statistics version 24 (International Business Machines, Armonk, NY).
Economic analysis
An economic analysis comparing the cost of routine duodenal biopsy against that of using Simtomax, EMA, and TTG to target biopsy for those with a positive result is demonstrated in especially in cases where the patient was referred from outside our local area. Th erefore, the cost of immunoglobulins were taken into account when calculating the cost of using TTG and EMA for the purpose of our analysis. As Simtomax detects both IgA DGP and IgG DGP, there is no need to check immunoglobulins for IgA defi ciency when using Simtomax as IgG DGP would be detected. Th erefore the cost of immunoglobulins were not included in the cost analysis for Simtomax.
RESULTS
A total of 217 patients with biopsy proven CD on a gluten-free diet were recruited from 2013 to 2017 (70% female, age range 16-83 years, median age 53 years). Th e median duration of the gluten free diet was 6 years (76.5 months; range: 6-900 months ). An economic analysis of using Simtomax, TTG, and EMA in CD monitoring is shown in Table 5 .
DISCUSSION
To our knowledge, this is the largest study evaluating the POCT, Simtomax, in disease monitoring, showing that Simtomax had a higher sensitivity than conventional serology and the adherence score in detecting ongoing VA. One of the strengths of this study is that duodenal biopsies were taken from all patients irrespective of their celiac antibody or adherence score results, ensuring that false negative cases would be taken into account when calculating the sensitivities and specifi cities of the surrogate markers. Th e only other published study investigating the role of Simtomax in disease monitoring was performed by Benkebil et al. ( 36 ) . Th e authors tested Simtomax and TTG in 46 patients with known CD, but only those with a positive TTG serology had duodenal biopsies taken. Th e sensitivity and specifi city of Simtomax were reported to be 78.9% and 95.7%, respectively. However, these results are unlikely to refl ect the true performance of Simtomax in disease monitoring, as only patients with a positive TTG were biopsied, which means false negative cases would be missed.
Ideally, the measurement of laboratory DGP assay alongside Simtomax would act as a useful comparison of the sensitivities between DGP detection by laboratory assay and lateral fl ow immunochromatography. However, laboratory DGP assays are not widely available in the UK and is not available in our center. Th erefore, DGP assays were not performed, which is a limitation ( 42, 44 ) . It is conceivable that the threshold for the generation of a positive result in Simtomax is not appropriate for disease monitoring purposes and the cutoff value cannot be adjusted similarly to laboratory serological titers, to identify the optimal cutoff numerical value. Furthermore, diff erent DGP peptides are used for diff erent DGP assays, thereby possibly giving diff erent levels of sensitivities. Although Simtomax performed signifi cantly better than the other surrogate markers, a sensitivity of 67% is not adequate for it to be used in isolation during follow up, nor is it adequate to replace duodenal biopsy. Combining Simtomax with the dietary of this study. In the UK, DGP is only performed within a few selective pediatric centers.
Laboratory DGP serology has been shown in several studies to be useful for disease monitoring in CD and appeared to be superior to TTG in this respect ( 41-44 ). Spatola et al. ( 42 ) showed that IgG-DGP was an eff ective surrogate marker for histological recovery, with a sensitivity and specifi city of 87 and 89% (at a positive threshold of 12 U ml adherence score only moderately raised the sensitivity to 70%.
Where there is a clinical suspicion of persistent VA, relying on using Simtomax alone to determine the need for a repeat biopsy may miss cases of VA, leading to potential complications.
On the other hand, one can also look at it from a diff erent perspective: Currently, we do not have a good surrogate marker for mucosal healing at hand. We believe that our study demonstrates that this simple POCT provides a stepwise increase in the diagnostic 
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IgA/IgG-DGP in Predicting Persistent VA be due to the signifi cantly lower prevalence of persistent VA in Bannister et al. ( 45 ) pediatric cohort (5.3%) compared with our adult cohort (39.2%), where a low prevalence population could lead to a high NPV for a diagnostic test. Indeed, previous follow up studies have demonstrated a slower and more incomplete mucosal healing in adults with CD treated with a gluten-free diet ( 11, (46) (47) (48) . Potential reasons for the low sensitivity of the adherence questionnaire include reliance on the patient's understanding of what foods contain gluten and their forthcomingness regarding their adherence. An economic analysis was performed for each surrogate marker and the gold standard of duodenal biopsy for the assessment of histological remission (see Table 5 ). Routine re-biopsy was found to be most expensive, costing £94436.23 (USD$123428.15) in our cohort, compared with taking biopsies only in patients with a positive serology or Simtomax, ranging from £25992.75 to £52646.09 (USD$33972.52 to 68808.44). Th e yield of persistent VA diff ered using diff erent methods, with the gold standard of routine rebiopsy detecting all cases of VA ( n =85), followed by Simtomax (57/85=67%), TTG (38/85=44.7%), and EMA (29/85=34%). When taking this into consideration, the cost to detect one case of VA was most expensive with routine re-biopsy and cheapest with TTG (£1111.01 (USD$1452.09), £923.62 (USD$1207.17), £896.30 (USD$1171.46), and £851.65 (USD$1113.11) for routine re-biopsy, Simtomax, EMA, and TTG, respectively). Overall, accuracy of a surrogate marker for persistent VA to an acceptable level in our search for a better test. Alongside the usual dietetic evaluation and symptom assessment, Simtomax could serve as a useful adjunct to provide instant DGP results during a follow-up consultation, not only for the benefi t of the clinicians but also as an immediate feedback for the patients which they highly value. With the use of a POCT during a clinic consultation, a face-to-face discussion between the clinician and the patient making a joint decision regarding the need for re-biopsy is made possible.
Th e low sensitivity of 44.7% for IgA-TTG in detecting persistent VA in our study is in line with what has been reported in the literature. For instance, Kaukinen et al. ( 26 ) reported the IgA-TTG sensitivity to be 41% and, more recently, 43.6% by Sharkey et al. ( 10 ) . Th e even lower sensitivity of 37.7% for IgA-EMA also mirrors the 26% sensitivity reported by Kaukinen et al. ( 26 ) .
Th e dietary adherence questionnaire was quick and simple to administer, but its performance in identifying patients with ongoing VA was disappointing in our study. Recent work by Bannister et al. ( 45 ) evaluated this adherence questionnaire and found that the adherence score had a similarly low correlation to VA, with a sensitivity, specifi city, and positive predictive value and NPV of 33%, 89%, 13%, and 97% respectively. Th e sensitivity and specifi city of the adherence score were consistent with our results of 24.7 and 86.4%; however, the positive predictive value and NPV were strikingly diff erent from our fi ndings. Th is could Simtomax was shown to be cheaper than routine re-biopsy, although slightly more expensive than conventional serology. Nevertheless, it is important for clinicians to consider not only the cost, but also the effi cacy of the surrogate markers and the invasiveness of a gastroscopy as a whole when deciding which method should be used for disease monitoring in CD.
To conclude, this study showed for the fi rst time that the commercially available DGP based POCT, Simtomax, had a superior sensitivity in detecting persistent VA in patients with known CD, compared with the adherence score and conventional celiac serology (TTG and EMA), which are routinely used for disease monitoring at the present time. Simtomax could help streamline the follow-up process by providing DGP results during the consultation and facilitate the joint decision-making between the clinician and the patient regarding the onward management plan such as the necessity of follow up duodenal biopsy. 
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ Persistent villous atrophy may increase the risk of complications in celiac disease.
✓ There are currently no reliable surrogate markers for persistent villous atrophy.
WHAT IS NEW HERE
✓ The DGP POCT had a signifi cantly higher sensitivity than conventional serology in detecting persistent villous atrophy.
✓ The DGP POCT could provide instant DGP results during follow-up consultations to facilitate onward management.
✓ The dietary adherence questionnaire had a low sensitivity in identifying ongoing villous atrophy.
